Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1312)	5/3/2002 7:23:32 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Great...new 52 week low. The following is a link to the MEDI presentation at CIBC yesterday...The following is a recap of their comments on investor.medimmune.com Siplizumab: Mechanism: selectively suppresses immune system Targets: T cell-mediated diseases ///psoriasis, psoriatic arthritis, t cell lymphoma, lung transplantations, GvHD, etc. Psoriasis Program: Phase I complete : SC and IV dosing well tolerated Phase II fully dosed: three trials; 665 patients total U.S. IV trial (n=124) European SC trail (n=121) U.S/Canada SC trial (n=420) Retreatment studies to start 1H02 Psoriatic arthritis studies to begin 1H02. Data from PHase II to be looked at this summer. Question to all:::: If they are starting the retreatment studies, would this not be based on the fact that these original patients had a positive outcome with their treatments. IMO, if I didn't like the results from this earlier treatment..why would I come back for seconds.